BioNexus Gene Lab Corp. (BGLC) Net margin 2018–2025
BioNexus Gene Lab Corp. (BGLC) net profit margin by fiscal year — reported net income divided by reported revenue.
-40.2%FY2025 · since FY2018: 12.5% → -40.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -40.2% | -23.4 pp |
| FY2024 | -16.8% | +10.1 pp |
| FY2023 | -26.9% | -23.6 pp |
| FY2022 | -3.3% | -8.9 pp |
| FY2021 | 5.6% | -4.0 pp |
| FY2020 | 9.6% | +203.7 pp |
| FY2019 | -194.1% | -206.6 pp |
| FY2018 | 12.5% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice